Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)

NCT02718066 is registered in ClinicalTrials.gov with HUYABIO International, LLC. as lead sponsor.

NCT NCT02718066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02718066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
HUYABIO International, LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
August 18, 2016
Completion date
December 12, 2023
Enrollment
96 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-small cell lung cancer, renal cell carcinoma